1. Home
  2. CHKP vs NBIX Comparison

CHKP vs NBIX Comparison

Compare CHKP & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Check Point Software Technologies Ltd.

CHKP

Check Point Software Technologies Ltd.

HOLD

Current Price

$135.87

Market Cap

15.3B

Sector

Technology

ML Signal

HOLD

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

HOLD

Current Price

$130.13

Market Cap

13.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHKP
NBIX
Founded
1993
1992
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.3B
13.2B
IPO Year
1997
1996

Fundamental Metrics

Financial Performance
Metric
CHKP
NBIX
Price
$135.87
$130.13
Analyst Decision
Buy
Strong Buy
Analyst Count
20
22
Target Price
$205.75
$180.82
AVG Volume (30 Days)
782.2K
901.1K
Earning Date
04-30-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
41.95
EPS
N/A
4.67
Revenue
N/A
$161,626,000.00
Revenue This Year
$8.28
$22.85
Revenue Next Year
$6.03
$10.36
P/E Ratio
$17.05
$27.09
Revenue Growth
N/A
977.51
52 Week Low
$134.38
$97.30
52 Week High
$233.78
$160.18

Technical Indicators

Market Signals
Indicator
CHKP
NBIX
Relative Strength Index (RSI) 34.56 50.14
Support Level N/A $124.29
Resistance Level $208.46 $136.23
Average True Range (ATR) 5.23 4.29
MACD -0.17 -0.08
Stochastic Oscillator 4.38 59.64

Price Performance

Historical Comparison
CHKP
NBIX

About CHKP Check Point Software Technologies Ltd.

Check Point Software Technologies is a pure-play cybersecurity vendor. The company offers solutions for network, endpoint, cloud, and mobile security in addition to security management. Check Point, a software specialist, sells to enterprises, businesses, and consumers. Around 50% of revenue is generated in Europe, the Middle East, and Africa, 40% from the Americas, and 10% from the Asia-Pacific region. The firm, based in Tel Aviv, Israel, was founded in 1993 and has about 5,000 employees.

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Share on Social Networks: